Table 2. Objective tumor response by... | American Society of Hematology

Table 2.

Objective tumor response by histological subtype

	MZL subtype
n (%)	Nodal MZL (n = 15)	MALT lymphoma (n = 4)	Splenic MZL (n = 4)	Total (N = 23)
CR	0	0	3 (75.0)	3 (13.0)
PR	13 (86.7)	2 (50.0)	0	15 (65.2)
ORR	13 (86.7)	2 (50.0)	3 (75.0)	18 (78.3)
Disease control rate	13 (86.7)	4 (100)	3 (75.0)	20 (87.0)
Stable disease	0	2 (50.0)	0	2 (8.7)
Not available*	2 (13.3)	0	0	2 (8.7)
Not evaluable†	0	0	1 (25.0)	1 (4.3)

	MZL subtype
n (%)	Nodal MZL (n = 15)	MALT lymphoma (n = 4)	Splenic MZL (n = 4)	Total (N = 23)
CR	0	0	3 (75.0)	3 (13.0)
PR	13 (86.7)	2 (50.0)	0	15 (65.2)
ORR	13 (86.7)	2 (50.0)	3 (75.0)	18 (78.3)
Disease control rate	13 (86.7)	4 (100)	3 (75.0)	20 (87.0)
Stable disease	0	2 (50.0)	0	2 (8.7)
Not available*	2 (13.3)	0	0	2 (8.7)
Not evaluable†	0	0	1 (25.0)	1 (4.3)

Includes patients with only post–baseline tumor assessment who could not be assessed.

†

Includes patients with no post–baseline tumor assessment, but who discontinued because of a drug-related toxicity, death, or progression by clinical judgment before disease was reevaluated.

View Large

This Feature Is Available To Subscribers Only